611 W. Union Street
Benson, AZ 85602
(520) 586-0800

LaFrontera
member support line
1-520-279-5737
M-F 5pm-8pm
24/7 weekends/holidays

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...


Medical Disorders
Resources
Basic InformationLookupsLatest News
What You Need to Know About Your Colon Cancer RiskNewer Rheumatoid Arthritis Drug May Help Ease Tough-to-Treat CasesCelebrate Autumn Traditions Without Raising Your COVID RiskNew Drug Could Extend Life for People With ALSHeart Defects Don't Increase Risk of Severe COVID-19Chinese COVID Vaccine Shows Promise in Early TrialAmerica Sees Daily COVID Cases Pass 60,000 Once AgainCOVID Scored Big at 'Superspreader' Hockey GameAHA News: Belly Fat May Signal Early Heart Issues for Mexican AmericansFDA Approves First Ebola Virus TreatmentAmericans Might Need to Pass on Thanksgiving Gatherings: FauciAHA News: Flu and COVID-19 Are Bad Enough, But They Also Can Raise Stroke RiskYour Blood Type May Predict Your Risk For Severe COVID-19Newborns of Moms With COVID-19 Face Little Infection Risk: StudyCOVID Cases Climbing in 36 StatesBedside COVID-19 Test Faster Than Standard PCR TestNIH Launches Trial of Antibody Drugs Against COVID-19Long-Lasting Immunity Seems to Follow Serious COVID CasesAHA News: How Much Do You Know About Thrombosis? Probably Not EnoughCOVID-19 Taking Huge Toll in Excess U.S. DeathsSecond COVID Vaccine Trial Paused for Unexplained IllnessBlacks, Asians More Likely Than Whites to Have Severe COVIDUpper Midwest Sees COVID-19 Surge as Northeast Worries About a Second WaveRemdesivir Speeds Recovery for COVID PatientsAnimal Study Points to Heating Coil Behind Serious Vaping InjuriesAHA News: Strokes and Heart Attacks Increase When Flu-Like Illnesses RiseZika Epidemic Was More Widespread Than Thought: StudyVirtual Care After Surgery May Be More Convenient For PatientsAlways Be Ready for a Trip to the ERPandemic Silver Lining: Steep Drop in Kids' FracturesAntibiotics May Be Best First Treatment for AppendicitisResearchers Identify Bacteria Responsible for Key Crohn's ComplicationDuring and After Surgery, Pot Users Need More Anesthesia, Painkillers: StudyHeart Patients Need to Be Wary of CoronavirusWearing a Mask Doesn't Cause CO2 PoisoningCOVID-19 ICU Patients Have High Risk of Clots, Research ShowsGot Sciatica? Stay Active and Start Early on Physical TherapyDrug Combo Approved for First-Line Treatment of Mesothelioma8 in 10 COVID-19 Patients Suffer Neurological Symptoms, Study FindsAs Virtual Doctor Visits Spike, Concerns About Equity, Missed Diagnoses GrowFor Maximum Safety, Be Sure to Wash Your Homemade Face Mask: StudyDo Minority Kids Face More Danger During Surgeries?Why Getting a Flu Shot is More Important Than Ever This FallCommon Heartburn Meds Tied to Higher Diabetes RiskCOVID-19 Antibodies Decline Quickly in Donated Plasma: StudyNormal Conversation Spreads Virus-Laden Droplets Beyond 6 FeetPresident Trump, First Lady Test Positive for CoronavirusGenetics Might Explain Some Cases of Cerebral PalsyWith 'Twindemic' Looming, 2 out of 5 Americans Plan to Skip Flu ShotLast-Ditch Life Support System Is Saving Lives of COVID Patients
Questions and AnswersLinksBook Reviews
Related Topics

Cancer
Men's Health
Women's Health

Chinese COVID Vaccine Shows Promise in Early Trial

HealthDay News
by -- Robert Preidt
Updated: Oct 16th 2020

new article illustration

FRIDAY, Oct. 16, 2020 (HealthDay News) -- An experimental COVID-19 vaccine appeared to be safe and triggered an immune response in healthy people, according to preliminary results of a small, early-stage clinical trial.

The study of the vaccine based on inactivated whole SARS-CoV-2 virus (BBIBP-CorV) included more than 600 volunteers in China, ages 18 to 80. By the 42nd day after vaccination, all had antibody responses to the virus, according to researchers.

The vaccine was safe and well-tolerated at all doses tested, study leaders reported. The most common side effect was pain at the injection site. There were no serious adverse reactions.

The findings were published Oct. 15 in The Lancet Infectious Diseases journal.

Similar results were reported from a previous trial for a different vaccine also based on inactivated whole SARS-CoV-2 virus. That trial was limited to people under age 60.

The new trial found that people 60 and older responded more slowly to the vaccine. It took 42 days for antibodies to be detected in all of them, compared to 28 days among 18- to 59-year-olds.

Antibody levels were also lower in 60- to 80-year-olds compared with the younger volunteers.

"Protecting older people is a key aim of a successful COVID-19 vaccine as this age group is at greater risk of severe illness from the disease. However, vaccines are sometimes less effective in this group because the immune system weakens with age," said study co-author Xiaoming Yang, a professor at Beijing Institute of Biological Products Company Limited.

"It is therefore encouraging to see that BBIBP-CorV induces antibody responses in people aged 60 and older, and we believe this justifies further investigation," Yang said in a journal news release.

Because the trial wasn't designed to assess the effectiveness of the BBIBP-CorV vaccine, it's not possible to know whether the antibody response it triggered is strong enough to protect people from infection with the new coronavirus.

After the researchers complete a full analysis of data from the adults, they plan to test the vaccine in children and teens under age 18.

Larisa Rudenko, a researcher at the Institute of Experimental Medicine in St. Petersburg, Russia, wrote an editorial that accompanied the findings.

She said more "studies are needed to establish whether the inactivated SARS-CoV-2 vaccines are capable of inducing and maintaining virus-specific T-cell responses."

More information

The U.S. Centers for Disease Control and Prevention has more on COVID-19.